arrow
P

Palak Trivedi

National Institute for Health and Care Research
H指数:49
被引数:7,640

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity

瘙痒在原发性硬化性胆管炎中常见,会持续存在,其强度与疾病严重程度相关。

2025-12-010
PRE
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

肝硬度测量的预后价值与生化反应在原发性胆汁性胆管炎中的比较

2025-10-030
PRE
Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis

II期INTEGRIS-PSC试验中,bexotegrast(一种αvβ6/αvβ1整合素抑制剂)用于原发性硬化性胆管炎的研究。

2025-09-260
PRE
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

对奥贝胆酸的非应答与原发性胆汁性胆管炎患者发生临床事件的风险增加相关

2025-09-220
OAAI
Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study

原发性胆汁性胆管炎患者提问提示清单的开发:一项德尔菲研究

2025-04-150
OAAI
Implementation of a care bundle improves PBC management

实施护理方案可改善PBC管理

2025-04-100
OAAI
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis

肝脏硬度测量的动力学和原发性胆汁性胆管炎的临床过程

2024-12-011
OAAI
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

原发性胆汁性胆管炎药物评估和监管批准: 我们从这里走向何方?

2024-03-226
OAAI
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
2024-02-011
PRE
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients

肝病患者和肝移植受者新型冠状病毒肺炎疫苗接种后的免疫反应和临床结局

2024-01-015
OAAI